{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:02:54Z","timestamp":1790355774094,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.vaccine.2012.09.057","type":"journal-article","created":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T06:30:15Z","timestamp":1349332215000},"page":"7046-7051","source":"Crossref","is-referenced-by-count":56,"title":["A Vaxfectin\u00ae-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes"],"prefix":"10.1016","volume":"30","author":[{"given":"Ronald L.","family":"Veselenak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shlapobersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Pyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.09.057_bib0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle","year":"2008","journal-title":"Annu Rev Med"},{"issue":"April (15)","key":"10.1016\/j.vaccine.2012.09.057_bib0010","first-page":"456","article-title":"Seroprevalence of herpes simplex virus type 2 among persons aged 14\u201349 years \u2013 United States, 2005\u20132008","volume":"59","author":"Xu","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"May (9267)","key":"10.1016\/j.vaccine.2012.09.057_bib0015","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2012.09.057_bib0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ije\/26.4.698","article-title":"Genital herpes infection: a review","volume":"26","author":"Brugha","year":"1997","journal-title":"Int J Epidemiol"},{"issue":"April (14)","key":"10.1016\/j.vaccine.2012.09.057_bib0025","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.09.057_bib0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.79.1.410-418.2005","article-title":"Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs","volume":"79","author":"Hoshino","year":"2005","journal-title":"J Virol"},{"issue":"March (Suppl. 1)","key":"10.1016\/j.vaccine.2012.09.057_bib0035","first-page":"6A","article-title":"The Holy Grail: immune control of human herpes simplex virus infection and disease","volume":"8","author":"Cunningham","year":"2001","journal-title":"Herpes"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.09.057_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.09.057_bib0045","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/CVI.00167-08","article-title":"Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system","volume":"15","author":"Cattamanchi","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.057_bib0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0163-7258(97)82003-7","article-title":"DNA vaccines","volume":"74","author":"Montgomery","year":"1997","journal-title":"Pharmacol Ther"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2012.09.057_bib0055","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1086\/315879","article-title":"Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses","volume":"182","author":"Higgins","year":"2000","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2012.09.057_bib0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1348-0421.1999.tb02393.x","article-title":"Genes that induce immunity\u2014DNA vaccines","volume":"43","author":"Sasaki","year":"1999","journal-title":"Microbiol Immunol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.09.057_bib0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/infdis\/173.4.800","article-title":"DNA immunization against experimental genital herpes simplex virus infection","volume":"173","author":"Bourne","year":"1996","journal-title":"J Infect Dis"},{"issue":"February (15\u201316)","key":"10.1016\/j.vaccine.2012.09.057_bib0070","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0264-410X(00)00445-X","article-title":"Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens","volume":"19","author":"Hartikka","year":"2001","journal-title":"Vaccine"},{"issue":"June (27)","key":"10.1016\/j.vaccine.2012.09.057_bib0075","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/S0264-410X(01)00090-1","article-title":"Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization","volume":"19","author":"Reyes","year":"2001","journal-title":"Vaccine"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2012.09.057_bib0080","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1517\/17425247.2010.538047","article-title":"Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines","volume":"7","author":"Sullivan","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2012.09.057_bib0085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1099\/vir.0.040055-0","article-title":"Vaxfectin(R)-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection","volume":"93","author":"Shlapobersky","year":"2012","journal-title":"J Gen Virol"},{"issue":"May (Pt. 5)","key":"10.1016\/j.vaccine.2012.09.057_bib0090","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1099\/vir.0.008771-0","article-title":"Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB\/c mice after DNA immunization and infection","volume":"90","author":"Muller","year":"2009","journal-title":"J Gen Virol"},{"issue":"October (22)","key":"10.1016\/j.vaccine.2012.09.057_bib0095","doi-asserted-by":"crossref","first-page":"12899","DOI":"10.1073\/pnas.2131705100","article-title":"Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor","volume":"100","author":"Koelle","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2012.09.057_bib0100","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/374002","article-title":"Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs","volume":"187","author":"Bourne","year":"2003","journal-title":"J Infect Dis"},{"issue":"July (3)","key":"10.1016\/j.vaccine.2012.09.057_bib0105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jmv.20365","article-title":"Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay","volume":"76","author":"Corey","year":"2005","journal-title":"J Med Virol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2012.09.057_bib0110","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1086\/498247","article-title":"Impact of immunization with glycoprotein D2\/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected","volume":"192","author":"Bourne","year":"2005","journal-title":"J Infect Dis"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2012.09.057_bib0115","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/315878","article-title":"Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs","volume":"182","author":"Strasser","year":"2000","journal-title":"J Infect Dis"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2012.09.057_bib0120","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1128\/JVI.02659-05","article-title":"Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes","volume":"80","author":"Hosken","year":"2006","journal-title":"J Virol"},{"issue":"December (23)","key":"10.1016\/j.vaccine.2012.09.057_bib0125","doi-asserted-by":"crossref","first-page":"12452","DOI":"10.1128\/JVI.01364-09","article-title":"Herpes simplex virus requires VP11\/12 to induce phosphorylation of the activation loop tyrosine (Y394) of the Src family kinase Lck in T lymphocytes","volume":"83","author":"Wagner","year":"2009","journal-title":"J Virol"},{"issue":"December (Pt. 12)","key":"10.1016\/j.vaccine.2012.09.057_bib0130","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1099\/0022-1317-70-12-3177","article-title":"Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy","volume":"70","author":"Stanberry","year":"1989","journal-title":"J Gen Virol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.09.057_bib0135","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/infdis\/153.6.1055","article-title":"Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs","volume":"153","author":"Stanberry","year":"1986","journal-title":"J Infect Dis"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2012.09.057_bib0140","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/infdis\/170.5.1110","article-title":"The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine","volume":"170","author":"Burke","year":"1994","journal-title":"J Infect Dis"},{"issue":"November (1\u20133)","key":"10.1016\/j.vaccine.2012.09.057_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0166-3542(88)90016-2","article-title":"Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs","volume":"10","author":"Myers","year":"1988","journal-title":"Antiviral Res"},{"issue":"June (8911)","key":"10.1016\/j.vaccine.2012.09.057_bib0150","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(94)92581-X","article-title":"Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes","volume":"343","author":"Straus","year":"1994","journal-title":"Lancet"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2012.09.057_bib0155","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/514103","article-title":"Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial","volume":"176","author":"Straus","year":"1997","journal-title":"J Infect Dis"},{"issue":"August (Suppl. 3)","key":"10.1016\/j.vaccine.2012.09.057_bib0160","first-page":"130A","article-title":"Herpes simplex virus type 2 transmission: risk factors and virus shedding","volume":"11","author":"Wald","year":"2004","journal-title":"Herpes"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.09.057_bib0165","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.09.057_bib0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N Engl J Med"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2012.09.057_bib0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/sti.2002.003848","article-title":"The potential epidemiological impact of a genital herpes vaccine for women","volume":"80","author":"Garnett","year":"2004","journal-title":"Sex Transm Infect"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.09.057_bib0180","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI1758","article-title":"Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes","volume":"101","author":"Koelle","year":"1998","journal-title":"J Clin Invest"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T23:48:01Z","timestamp":1643500081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12013771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":36,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0264410X12013771"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}